Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology ...
Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
Glucocorticoid use, excluding dexamethasone, was not associated with reduced overall survival among patients with mNSCLC and RA who initiated ICI therapy.
Johnson & Johnson’s Darzalex Faspro-based quadruplet regimen approved in US for newly diagnosed patients with multiple myeloma who are transplant ineligible: Horsham, Pennsylvan ...
FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
This case study is one in a set of patient safety ‘how we acted on patient safety issues you recorded’ case studies which ...
FRIDAY, Jan. 23, 2026 (HealthDay News) — Brain tumors are abnormal growths of cells in or around the brain. They can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results